Claims

1. The compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof, wherein the compound is selected from:

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)butylamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)hexanamide;


N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)cyclopropanecarboxamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)isobutylamide;

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)pivalamide; and

N-((R)-((1S,2R,3S,5S,7S)-5-chloro-1-hydroxyadamantan-2-yl)(phenyl)methyl)cyclopentanecarboxamide.

2. The compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof, wherein the compound is represented by Formula (Ic):



(Ic)

wherein R^6 is selected from C_{3-6} cycloalkyl;

R^3 represents phenyl optionally substituted with one or two halogen atoms.

3. A pharmaceutical composition comprising the compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according to Claim 1 or 2.

4. The pharmaceutical composition according to Claim 3, for use in treating or preventing a cognitive disease or disorder.

5. The pharmaceutical composition according to Claim 4, wherein the cognitive disease or disorder is selected from Alzheimer's dementia, cerebrovascular dementia, Lewy body dementia, frontotemporal dementia, Parkinson's disease, a mental disease and a neurodegenerative disease.

6. The pharmaceutical composition according to Claim 3, for use in treating or preventing diabetes or a diabetic complication.

7. A Kir6.2 channel inhibitor comprising the compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according Claim 1 or 2.

8. A Kir6.1 channel inhibitor comprising the compound, enantiomer thereof, diastereomer thereof, or pharmaceutically acceptable salt thereof according to Claim 1 or 2.